Canada: Amendments To The Patented Medicines (Notice Of Compliance) Regulations And Food And Drug Regulations

On October 5, 2006, the government of Canada passed substantive amendments to the Patented Medicines (Notice of Compliance) Regulations (the PM(NOC) Regulations) and the data protection provisions of the Food and Drug Regulations (the FD Regulations).

According to the Regulatory Impact Analysis Statement (RIAS) issued by the government to explain the proposed amendments, the purpose of these amendments is to restore the balance between the rights of patent holding drug manufacturers (innovators) and the generic drug manufacturers (generics), in order to ensure a balance between the two policy goals of effectively protecting pharmaceutical inventions (in order to stimulate research and development) and keeping the cost of medicines down.

Although there are a number of changes to the PM(NOC) Regulations, two amendments were particularly significant: (i) a "frozen" patent register and (ii) refined patent listing requirements. In addition, one of the amendments to the FD Regulations (the Data Protection Amendments), which provides for a six-year no-filing period for generic manufacturers and a minimum of an eight-year period of market exclusivity to innovators, is of particular importance.

PM(NOC) Regulations Amendments

The PM(NOC) Regulations provide for a framework permitting pharmaceutical patents to be listed on Health Canada’s patent register. The Regulations link the Minister of Health’s ability to approve a generic drug to the patent status of the innovator’s product by requiring the generic to address the patents listed on the patent register before a notice of compliance (NOC) is issued by the Minister.

If a generic serves an innovator with a notice of allegations (NOA), alleging that each of the patents on the register are not infringed by the generic or are invalid, the innovator may bring an application to the Federal Court to prohibit the Minister from issuing an NOC to the generic. Once such an application has been made, an automatic twenty-four-month stay comes into in effect. This prevents the Minister from issuing the NOC to the generic until the issues of infringement and invalidity are addressed.

Frozen Patent Register

Prior to these amendments, if a patent was added to the patent register after the generic had filed an abbreviated new drug submission (ANDS) for an NOC, but before the NOC was issued, the generic had to amend the ANDS and serve a new NOA in order to address the newly added patent. This process—sometimes referred to as "evergreening"— effectively gave innovators the ability to invoke multiple twenty-four-month stays in order to extend the terms of their monopolies.

Under the amendments, the patent register is now "frozen" as of the date of filing of the generic’s ANDS. The generic no longer needs to address any patents listed on the register by the innovator subsequent to that date: only patents that are on the register at the time of its drug submission need to be adressed. For submissions filed prior to October 5, 2006, the patent register is considered frozen as of October 5, 2006.

The "freezing" of the patent register is considered by many to be a significant gain for the generics.

Refined Listing Requirements

The amendments also refine the listing requirements under s. 4 of the PM(NOC) Regulations. Under the new requirements, a patent can be listed on the patent register with a new drug submission (NDS) if it contains a claim for the medicinal ingredient itself, the formulation, the dosage form, or a claim for a use of the medicinal ingredient. Each of these claims must be approved claims.

The amendments also increase the scope of eligible subject matter for patents to be listed. Previously, courts have consistently held that "claim for the medicine itself" in s. 4 was insufficient to support the listing of dosage form patents. The amendments contain explicit language changing the allowable subject matter to include dosage form patents.

Prior to the amendments, a patent could be listed with almost any supplement to a new drug submission (SNDS), with the exception of an SNDS filed for an administrative change such as a name change. Under the new requirements, a patent that has been applied for prior to the filing of a SNDS may be submitted with the SNDS, provided the purpose of the SNDS is to obtain approval for a change in the use of the medicinal ingredient, formulation, or dosage form. In addition, the patent can only be listed if it claims the use of the medicinal ingredient, formulation, or dosage form for which approval is sought.

It has been argued, notwithstanding the expansion of subject matter to include dosage form patents, that the new listing requirements are far stricter than the previous regulations, and thus, a loss for the innovators.

The new patent listing eligibility requirements do not apply to patents listed before June 17, 2006.

Data Protection Amendments

The Data Protection Amendments are intended to clarify and effectively implement Canada's obligations under the North American Free Trade Agreement and the WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement with respect to data protection. These obligations require that signatories provide protection against the unfair commercial use of undisclosed tests or other data submitted in order to obtain approval of pharmaceutical or agricultural chemical products that utilize new chemical entities. The intent of this protection is to allow the originator of the data to protect the investments made in the development of the product by allowing a period of market exclusivity.

Under the previous FD Regulations, data protection arises when the Minister examines and relies on an innovator's undisclosed data in order to grant a NOC to a generic. The previous data protection provisions were intended to guarantee the confidentiality and non-use of the innovator’s data for a period of five-years from the date of issuance of the NOC to the innovator. However, to receive an NOC in Canada, a generic need only demonstrate bioequivalence by comparing its generic product to the innovator's product. Therefore, in actual practice, the Minister typically does not examine the data contained in the innovator's submission in order to grant a NOC for a generic product. As a result, data protection did not arise where bioequivalence formed the basis of a generic submission (see Bayer v. Attorney General of Canada (1999), 87 C.P.R. (3d) 293 (Federal Court of Appeal)).

The FD Regulations have been amended to prohibit the granting of a NOC to a generic for eight years from the issuance of the innovator’s NOC. A six-month extension is added to this time if the innovator designed and conducted clinical trials for use of the drug in paediatric populations. In addition, within the eight-year period, the generic is not able to file a drug submission until six years after the date in which the NOC was issued to the innovator. The amendments also require the Minister to maintain a register of innovative drugs.

These amendments have been considered a significant win for innovators. Combined with another amendment to the PM(NOC) Regulations that prohibits a NOA from being filed until an ANDS has been submitted to the Minister, these amendments provide the innovator with a six-year period to get all relevant patents issued and listed on the register.

The Data Protection Amendments apply to drugs that have received an NOC on or after June 17, 2006. If a generic has already filed a submission for a generic version of a drug that would otherwise benefit from the new data-protection term, the filing date of the submission will be deemed to be six years from the day on which the first NOC was issued for the innovative drug.

The Canadian Generic Pharmaceutical Association has recently announced the launch of a suit in Federal Court, which requests that the Federal Court quash the provisions of the PM(NOC) Regulations which give innovator drug firms additional years of data protection.

Additional Amendments

Detailed information regarding several other amendments to the PM(NOC) Regulations and FD Regulations are available online at the websites below.

PM(NOC) Regulations

FD Regulations

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions